ADHD and Substance Use Disorders in Young People : Considerations for Evaluation, Diagnosis, and Pharmacotherapy - 11/06/22
![](/templates/common/images/mail.png)
Résumé |
Co-occurring ADHD and substance use disorder (SUD) is a common clinical presentation associated with significant impairment requiring careful evaluation, diagnosis, and treatment. Treatment with medication, along with cognitive behavioral therapy, is generally regarded as effective in addressing symptoms and impairments associated with both disorders. Options for pharmacotherapy include stimulant and nonstimulant therapies administered with careful monitoring of dosage and compliance to optimize efficacy. In high-risk groups such as college students and/or those with SUD, prescribers should address risks of stimulant misuse and diversion through patient and family education, medication monitoring, and other risk-reducing practices.
Le texte complet de cet article est disponible en PDF.Keywords : Attention-deficit/hyperactivity disorder, ADHD, Substance use disorder, SUD, Comorbidity, Pharmacotherapy, Treatment
Plan
Vol 31 - N° 3
P. 515-530 - juillet 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?